Physician profile
Gopal Sachdeva
NPI 1447449509
$9,754.39
in general payments reported to CMS, 2019-2025
66 companies · $2,606 in 2025
The $2,606 reported for 2025 was more than what 91% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,739 · 2020: $135 · 2021: $480 · 2022: $689 · 2023: $1,850 · 2024: $2,255 · 2025: $2,606.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,525 · Education: $186.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,524.94 |
| Education | $186.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $1,005.05 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Astrazeneca Pharmaceuticals Lp | $897.99 | 2019-2025 | Imfinzi, Tagrisso, Enhertu |
| Novartis Pharmaceuticals Corporation | $629.10 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $616.64 | 2019-2025 | Iclusig, Ninlaro, Fruzaqla |
| Daiichi Sankyo INC. | $529.80 | 2019-2025 | Enhertu, Datroway |
| Janssen Biotech, INC. | $422.67 | 2019-2025 | Carvykti, Erleada, Balversa |
| Amgen INC. | $366.12 | 2019-2023 | Kyprolis, Blincyto, Lumakras |
| Seagen INC. | $326.34 | 2019-2023 | Padcev, Tukysa |
| Myriad Genetic Laboratories, INC. | $293.56 | 2023 | Prolaris, Myrisk, Precisetumor |
| Astellas Pharma US INC | $266.31 | 2019-2023 | Xospata |
| Pfizer INC. | $255.25 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $246.81 | 2019-2025 | Libtayo |
| Glaxosmithkline, LLC. | $231.20 | 2022-2025 | Zejula, Jemperli, Ojjaara |
| Bayer Healthcare Pharmaceuticals INC. | $229.92 | 2019-2025 | |
| Celgene Corporation | $209.62 | 2019-2025 | Breyanzi |
Show all 66 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gopal Sachdeva listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.